Thomas Smith
Stock Analyst at Leerink Partners
(2.32)
# 2,576
Out of 4,944 analysts
67
Total ratings
29.51%
Success rate
14.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $0.93 | +7.53% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $1.81 | +397.24% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $1.70 | +311.76% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $4.42 | +556.11% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $11.81 | +230.23% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $9.58 | +171.40% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $80 | $10.70 | +647.66% | 2 | Feb 21, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $69.89 | -71.38% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $646.60 | -32.73% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $61.10 | -41.08% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.36 | +196.61% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $15.89 | +32.16% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $18.86 | +138.66% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $7.60 | -21.05% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $3.73 | +60.86% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.83 | +502.92% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $55.65 | -69.45% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $24.99 | +156.10% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $16.99 | +312.01% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $9.14 | +217.29% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $2.60 | +900.00% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $41.27 | -70.92% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $4.08 | +145.22% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $3.36 | +11,804.76% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $13.90 | +475.54% | 2 | Dec 8, 2020 |
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.93
Upside: +7.53%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $1.81
Upside: +397.24%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $1.70
Upside: +311.76%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $4.42
Upside: +556.11%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $11.81
Upside: +230.23%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $9.58
Upside: +171.40%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $80
Current: $10.70
Upside: +647.66%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $69.89
Upside: -71.38%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $646.60
Upside: -32.73%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $61.10
Upside: -41.08%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.36
Upside: +196.61%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $15.89
Upside: +32.16%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $18.86
Upside: +138.66%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $7.60
Upside: -21.05%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $3.73
Upside: +60.86%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.83
Upside: +502.92%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $55.65
Upside: -69.45%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $24.99
Upside: +156.10%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $16.99
Upside: +312.01%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $9.14
Upside: +217.29%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.60
Upside: +900.00%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $41.27
Upside: -70.92%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $4.08
Upside: +145.22%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $3.36
Upside: +11,804.76%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $13.90
Upside: +475.54%